Oligoclonal bands: clinical utility and interpretation cues

References

• Freedman MS, Thompson EJ, Deisenhammer F, et al. Recommended standard of cerebrospinal fluid analysis in the diagnosis of multiple sclerosis: a consensus statement. Arch Neurol. 2005;62(6):865–870.
   PubMed Web of Science ®Google Scholar
• Keir G, Luxton RW, Thompson EJ. Isoelectric focusing of cerebrospinal fluid immunoglobulin G: an annotated update. Ann Clin Biochem. 1990;27(5):436–443.
   PubMedGoogle Scholar
• Gastaldi M, Zardini E, Leante R, et al. Cerebrospinal fluid analysis and the determination of oligoclonal bands. Neurol Sci. 2017;38(2):217–224.
   PubMedGoogle Scholar
• Poser CM, Paty DW, Scheinberg L, et al. New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann Neurol. 1983;13(3):227–231.
   PubMed Web of Science ®Google Scholar
• Dobson R, Ramagopalan S, Davis A, et al. Cerebrospinal fluid oligoclonal bands in multiple sclerosis and clinically isolated syndromes: a Meta-analysis of prevalence, prognosis and effect of latitude. J Neurol Neurosurg Psychiatry. 2013;84(8):909–914.
   PubMed Web of Science ®Google Scholar
• Abdelhak A, Hottenrott T, Mayer C, et al. CSF profile in primary progressive multiple sclerosis: re-exploring the basics. PLoS One. 2017;12(8):e0182647–12.
   PubMed Web of Science ®Google Scholar
• Berek K, Bsteh G, Auer M, et al. Cerebrospinal fluid findings in 541 patients with clinically isolated syndrome and multiple sclerosis: a monocentric study. Front Immunol. 2021;12:675307.
   PubMed Web of Science ®Google Scholar
• Matute-Blanch C, Villar LM, Álvarez-Cermeño JC, et al. Neurofilament light chain and oligoclonal bands are prognostic biomarkers in radiologically isolated syndrome. Brain. 2018;141(4):1085–1093.
   PubMedGoogle Scholar
• Jarius S, Paul F, Franciotta D, et al. Cerebrospinal fluid findings in aquaporin-4 antibody positive neuromyelitis optica: results from 211 lumbar punctures. J Neurol Sci. 2011;306(1–2):82–90.
   PubMed Web of Science ®Google Scholar
• Jurynczyk M, Messina S, Woodhall MR, et al. Clinical presentation and prognosis in MOG-antibody disease : a UK study. Brain. 2017;140(12):3128–3138.
   PubMedGoogle Scholar
• Jarius S, Pellkofer H, Siebert N, et al. Cerebrospinal fluid findings in patients with myelin oligodendrocyte glycoprotein (MOG) antibodies. Part 1 : results from 163 lumbar punctures in 100 adult patients. J Neuroinflamm. 2020;17(1):261.
   PubMed Web of Science ®Google Scholar
• Sechi E, Buciuc M, Flanagan EP, et al. Variability of cerebrospinal fluid findings by attack phenotype in myelin oligodendrocyte glycoprotein-IgG-associated disorder. Mult Scler Relat Disord. 2021;47:102638.
   PubMed Web of Science ®Google Scholar
• Cobo-Calvo A, Ruiz A, Maillart E, et al. Clinical spectrum and prognostic value of CNS MOG autoimmunity in adults: the MOGADOR study. Neurology. 2018;90(21):e1858–e1869.
   PubMed Web of Science ®Google Scholar
• Blinder T, Lewerenz J. Cerebrospinal fluid findings in patients with autoimmune encephalitis-a systematic analysis. Front Neurol. 2019;10:804.
   PubMed Web of Science ®Google Scholar
• Zrzavy T, Höftberger R, Wimmer I, et al. Longitudinal CSF findings in autoimmune encephalitis—a monocentric cohort study. Front Immunol. 2021;12:646940.
   PubMed Web of Science ®Google Scholar
• Dürr M, Nissen G, Sühs KW, et al. CSF findings in acute NMDAR and LGI1 antibody–associated autoimmune encephalitis. Neurol Neuroimmunol Neuroinflamm. 2021;8(6):e1086.
   PubMed Web of Science ®Google Scholar
• Dalmau J, Graus F, Villarejo A, et al. Clinical analysis of anti-Ma2-associated encephalitis. Brain. 2004;127(8):1831–1844.
   PubMed Web of Science ®Google Scholar
• Gultekin SH, Rosenfeld MR, Voltz R, et al. Paraneoplastic limbic encephalitis: neurological symptoms, immunological findings and tumour association in 50 patients. Brain. 2000;123(7):1481–1494.
   PubMed Web of Science ®Google Scholar
• Dade M, Berzero G, Izquierdo C, et al. Neurological syndromes associated with anti-gad antibodies. Int J Mol Sci. 2020;21:1–22.
   Web of Science ®Google Scholar
• Dorresteijn LDA, Kappelle AC, Renier WO, et al. Anti-amphiphysin associated limbic encephalitis: a paraneoplastic presentation of small-cell lung carcinoma [2]. J Neurol. 2002;249(9):1307–1308.
   PubMed Web of Science ®Google Scholar
• Antoine JC, Absi L, Honnorat J, et al. Antiamphiphysin antibodies are associated with various paraneoplastic neurological syndromes and tumors. Arch Neurol. 1999;56(2):172–177.
   PubMedGoogle Scholar
• Flanagan EP, Hinson SR, Lennon VA, et al. Glial fibrillary acidic protein immunoglobulin G as biomarker of autoimmune astrocytopathy: analysis of 102 patients. Ann Neurol. 2017;81(2):298–309.
   PubMed Web of Science ®Google Scholar
• Dumonceau AG, Ameli R, Rogemond V, et al. Glial fibrillary acidic protein autoimmunity: a french cohort study. Neurology. 2021;98(6):e653–e668.
   PubMed Web of Science ®Google Scholar
• Arun T, Pattison L, Palace J. Distinguishing neurosarcoidosis from multiple sclerosis based on CSF analysis: a retrospective study. Neurology. 2020;94(24):e2545–e2554.
   PubMed Web of Science ®Google Scholar
• Kidd DP. Sarcoidosis of the Central nervous system : clinical features, imaging, and CSF results. J Neurol. 2018;265(8):1906–1915.
   PubMed Web of Science ®Google Scholar
• Winfield JB, Shaw M, Silverman L, et al. Intrathecal IgG synthesis and blood-brain barrier impairment in patients with systemic lupus erythematosus and central nervous system dysfunction . Am J Med. 1983;74(5):837–844.
   PubMed Web of Science ®Google Scholar
• Trysberg E, Nylen K, Rosengren LE, et al. Neuronal and astrocytic damage in systemic lupus erythematosus patients with Central nervous system involvement. Arthritis Rheum. 2003;48(10):2881–2887.
   PubMedGoogle Scholar
• Kraemer M, Berlit P. Primary Central nervous system vasculitis: clinical experiences with 21 new european cases. Rheumatol Int. 2011;31(4):463–472.
   PubMed Web of Science ®Google Scholar
• Saruhan-Direskeneli G, Yentür SP, Mutlu M, et al. Intrathecal oligoclonal IgG bands are infrequently found in neuro-Behçet’s disease. Clin Exp Rheumatol. 2013;31:25–27.
   PubMed Web of Science ®Google Scholar
• Motomura S, Tabira T, Kuroiwa Y. A clinical comparative study of multiple sclerosis and neuro-Behçet's syndrome. J Neurol Neurosurg Psychiatry. 1980;43(3):210–213.
   PubMed Web of Science ®Google Scholar
• Burgoon MP, Hammack BN, Owens GP, et al. Oligoclonal immunoglobulins in cerebrospinal fluid during varicella zoster virus (VZV) vasculopathy are directed against VZV. Ann Neurol. 2003;54(4):459–463.
   PubMed Web of Science ®Google Scholar
• Mclean BN, Luxton RW, Thompson EJ. A study of immunoglobulin G in the cerebrospinal fluid of 1007 patients with suspected neurological disease using isoelectric focusing and the log IgG-index: a comparison and diagnostic applications. Brain. 1990;113(5):1269–1289.
   PubMedGoogle Scholar
• Coyle PK. Borrelia burgdorferi infection: clinical diagnostic techniques. Immunol Invest. 1997;26(1–2):117–128.
   PubMed Web of Science ®Google Scholar
• Lambin P, Gervais A, Levy M, et al. Intrathecal synthesis of IgG subclasses in multiple sclerosis and in acquired immunodeficiency syndrome (AIDS). J Neuroimmunol. 1991;35(1–3):179–189.
   PubMed Web of Science ®Google Scholar
• Bourahoui A, De Seze J, Guttierez R, et al. CSF isoelectrofocusing in a large cohort of MS and other neurological diseases. Eur J Neurol. 2004;11(8):525–529.
   PubMed Web of Science ®Google Scholar
• Chu AB, Sever JL, Madden DL, et al. Oligoclonal IgG bands in cerebrospinal fluid in various neurological diseases. Ann Neurol. 1983;13(4):434–439.
   PubMed Web of Science ®Google Scholar
• Mazzarello P, Poloni M, Ceroni M, et al. Is progressive multifocal leukoencephalopathy associated with intrathecal IgG synthesis? J Neuroimmunol. 1985;10(2):167–172.
   PubMed Web of Science ®Google Scholar
• Haertle M, Kallweit U, Weller M, et al. The presence of oligoclonal IgG bands in human CSF during the course of neurological diseases. J Neurol. 2014;261(3):554–560.
   PubMed Web of Science ®Google Scholar
• Erdem H, Ozturk-Engin D, Cag Y, et al. Central nervous system infections in the absence of cerebrospinal fluid pleocytosis. Int J Infect Dis. 2017;65(65):107–109.
   PubMedGoogle Scholar
• Skoog I, Wallin A, Fredman P, et al. A population study on blood-brain barrier function in 85-year-olds: relation to Alzheimer’s disease and vascular dementia. Neurology. 1998;50(4):966–971.
   PubMed Web of Science ®Google Scholar
• Jesse S, Brettschneider J, Sussmuth SD, et al. Summary of cerebrospinal fluid routine parameters in neurodegenerative diseases. J Neurol. 2011;258(6):1034–1041.
   PubMed Web of Science ®Google Scholar
• Dalakas MC, Houff SA, Engel WK, et al. CSF “monoclonal” bands in chronic relapsing polyneuropathy. Neurology. 1980;30(8):864–867.
   PubMed Web of Science ®Google Scholar
• Illes Z, Blaabjerg M. Cerebrospinal fluid findings in Guillain–barré syndrome and chronic inflammatory demyelinating polyneuropathies. Handb Clin Neurol. 2017;146:125–138.
   PubMedGoogle Scholar
• Krüger H, Englert D, Pflughaupt KW. Demonstration of oligoclonal immunoglobulin G in Guillain-Barré syndrome and lymphocytic meningoradiculitis by isoelectric focusing. J Neurol. 1981;226(1):15–24.
   PubMed Web of Science ®Google Scholar
• Segurado OG, Krüger H, Mertens HG. Clinical significance of serum and CSF findings in the Guillain-Barré syndrome and related disorders. J Neurol. 1986;233(4):202–208.
   PubMed Web of Science ®Google Scholar
• Karcher D, Van Sande M, Lowenthal A. Micro-electrophoresis in agar gel of proteins of the cerebrospinal fluid and Central nervous system. J Neurochem. 1959;4(2):135–140.
   PubMed Web of Science ®Google Scholar
• Holmøy T. The discovery of oligoclonal bands: a 50-year anniversary. Eur Neurol. 2009;62(5):311–315.
   PubMed Web of Science ®Google Scholar
• Link H, Huang YM. Oligoclonal bands in multiple sclerosis cerebrospinal fluid: an update on methodology and clinical usefulness. J Neuroimmunol. 2006;180(1–2):17–28.
   PubMed Web of Science ®Google Scholar
• Schwenkenbecher P, Konen FF, Wurster U, et al. The persisting significance of oligoclonal bands in the dawning era of kappa free light chains for the diagnosis of multiple sclerosis. Int J Mol Sci. 2018;19:3796.
   PubMed Web of Science ®Google Scholar
• Duell F, Evertsson B, Al Nimer F, et al. Diagnostic accuracy of intrathecal kappa free light chains compared with OCBs in MS. Neurol Neuroimmunol Neuroinflamm. 2020;7(4):e775–e778.
   PubMed Web of Science ®Google Scholar
• Gastaldi M, Zardini E, Franciotta D. An update on the use of cerebrospinal fluid analysis as a diagnostic tool in multiple sclerosis. Expert Rev Mol Diagn. 2017;17(1):31–46.
   PubMed Web of Science ®Google Scholar
• Franciotta D, Lolli F. Interlaboratory reproducibility of isoelectric focusing in oligoclonal band detection. Clin Chem. 2007;53(8):1557–1558.
   PubMed Web of Science ®Google Scholar
• Andersson M, Alvarez-Cermeñio J, Bernardi G, et al. Cerebrospinal fluid in the diagnosis of multiple sclerosis: a consensus report. J Neurol Neurosurg Psychiatry. 1994;57(8):897–902.
   PubMed Web of Science ®Google Scholar
• Mariotto S, Ferraro D, Soldani F, et al. Inter-center agreement in the interpretation of oligoclonal bands. Clin Chem Lab Med. 2020;59:1–4.
   PubMed Web of Science ®Google Scholar
• Reiber H, Thompson EJ, Grimsley G, et al. Quality assurance for cerebrospinal fluid protein analysis: international consensus by an internet-based group discussion. Clin Chem Lab Med. 2003;41(3):331–337.
   PubMed Web of Science ®Google Scholar
• Berek K, Bsteh G, Auer M, et al. Cerebrospinal fluid findings in 541 patients with clinically isolated syndrome and multiple sclerosis: a monocentric study. Front Immunol. 2021;12:1–11.
   Web of Science ®Google Scholar
• Lechner-Scott J, Spencer B, De Malmanche T, et al. The frequency of CSF oligoclonal banding in multiple sclerosis increases with latitude. Mult Scler. 2012;18(7):974–982.
   PubMed Web of Science ®Google Scholar
• Annunziata P, Giorgio A, De Santi L, et al. Absence of cerebrospinal fluid oligoclonal bands is associated with delayed disability progression in relapsing-remitting MS patients treated with interferon-beta. J Neurol Sci. 2006;244(1–2):97–102.
   PubMed Web of Science ®Google Scholar
• Wolinsky JS, Narayana PA, O’Connor P, et al. Glatiramer acetate in primary progressive multiple sclerosis: results of a multinational, multicenter, double-blind, placebo-controlled trial. Ann Neurol. 2007;61(1):14–24.
   PubMed Web of Science ®Google Scholar
• Petzold A. Intrathecal oligoclonal IgG synthesis in multiple sclerosis. J Neuroimmunol. 2013;262(1–2):1–10.
   PubMed Web of Science ®Google Scholar
• Tintore M, Rovira À, Río J, et al. Defining high, medium and low impact prognostic factors for developing multiple sclerosis. Brain. 2015;138(Pt 7):1863–1874.
   PubMed Web of Science ®Google Scholar
• Kuhle J, Disanto G, Dobson R, et al. Conversion from clinically isolated syndrome to multiple sclerosis : a large multicentre study. Mult Scler. 2015;21(8):1013–1024.
   PubMed Web of Science ®Google Scholar
• Farina G, Magliozzi R, Pitteri M, et al. Increased cortical lesion load and intrathecal inflammation is associated with oligoclonal bands in multiple sclerosis patients: a combined CSF and MRI study. J Neuroinflammation. 2017;14(1):40.
   PubMedGoogle Scholar
• Ferreira D, Voevodskaya O, Imrell K, et al. Multiple sclerosis patients lacking oligoclonal bands in the cerebrospinal fluid have less global and regional brain atrophy. J Neuroimmunol. 2014;274(1–2):149–154.
   PubMed Web of Science ®Google Scholar
• Mancuso R, Franciotta D, Rovaris M, et al. Effects of natalizumab on oligoclonal bands in the cerebrospinal fluid of multiple sclerosis patients: a longitudinal study. Mult Scler. 2014;20(14):1900–1903.
   PubMed Web of Science ®Google Scholar
• Von Glehn F, Farias AS, De Oliveira ACP, et al. Disappearance of cerebrospinal fluid oligoclonal bands after natalizumab treatment of multiple sclerosis patients. Mult Scler. 2012;18(7):1038–1041.
   PubMed Web of Science ®Google Scholar
• Harrer A, Tumani H, Niendorf S, et al. Cerebrospinal fluid parameters of B cell-related activity in patients with active disease during natalizumab therapy. Mult Scler. 2013;19(9):1209–1212.
   PubMed Web of Science ®Google Scholar
• Rejdak K, Stelmasiak Z, Grieb P. Cladribine induces long lasting oligoclonal bands disappearance in relapsing multiple sclerosis patients: 10-year observational study. Mult Scler Relat Disord. 2019;27:117–120.
   PubMed Web of Science ®Google Scholar
• Thompson AJ, Banwell BL, Barkhof F, et al. Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. Lancet Neurol. 2018;17(2):162–173.
   PubMed Web of Science ®Google Scholar
• Arrambide G, Tintore M, Espejo C, et al. The value of oligoclonal bands in the multiple sclerosis diagnostic criteria. Brain. 2018;141(4):1075–1084.
   PubMedGoogle Scholar
• Lee DH, Peschke M, Utz KS, et al. Diagnostic value of the 2017 McDonald criteria in patients with a first demyelinating event suggestive of relapsing-remitting multiple sclerosis. Eur J Neurol. 2019;26(3):540–545.
   PubMed Web of Science ®Google Scholar
• Hartung HP, Graf J, Aktas O, et al. Diagnosis of multiple sclerosis: revisions of the McDonald criteria 2017 - Continuity and change. Curr Opin Neurol. 2019;32(3):327–337.
   PubMed Web of Science ®Google Scholar
• Solomon AJ, Naismith RT, Cross AH. Misdiagnosis of multiple sclerosis: impact of the 2017 McDonald criteria on clinical practice. Neurology. 2019;92(1):26–33.
   PubMed Web of Science ®Google Scholar
• Tintoré M, Rovira A, Brieva L, et al. Isolated demyelinating syndromes: comparison of CSF oligoclonal bands and different MR imaging criteria to predict conversion to CDMS. Mult Scler. 2001;7(6):359–363.
   PubMedGoogle Scholar
• Midaglia L, Sastre-Garriga J, Pappolla A, et al. The frequency and characteristics of MS misdiagnosis in patients referred to the multiple sclerosis Centre of Catalonia. Mult Scler. 2021;27(6):913–921.
   PubMed Web of Science ®Google Scholar
• Kaisey M, Solomon AJ, Luu M, et al. Incidence of multiple sclerosis misdiagnosis in referrals to two academic centers. Mult Scler Relat Disord. 2019;30:51–56.
   PubMed Web of Science ®Google Scholar
• Calabrese M, Gasperini C, Tortorella C, et al. “Better explanations” in multiple sclerosis diagnostic workup: a 3-year longitudinal study. Neurology. 2019;92(22):e2527–e2537.
   PubMed Web of Science ®Google Scholar
• Mailand MT, Frederiksen JL. Intrathecal IgM as a prognostic marker in multiple sclerosis. Mol Diagn Ther. 2020;24(3):263–277.
   PubMed Web of Science ®Google Scholar
• Capuano R, Zubizarreta I, Alba-Arbalat S, et al. Oligoclonal IgM bands in the cerebrospinal fluid of patients with relapsing MS to inform long-term MS disability. Mult Scler. 2021;27(11):1706–1711.
   PubMed Web of Science ®Google Scholar
• Nakano T, Matsui M, Inoue I, et al. Free immunoglobulin light chain: its biology and implications in diseases. Clin Chim Acta. 2011;412(11–12):843–849.
   PubMed Web of Science ®Google Scholar
• Leurs C, Twaalfhoven H, Lissenberg-Witte B, et al. Kappa free light chains is a valid tool in the diagnostics of MS: a large multicenter study. Mult Scler. 2020;26(8):912–923.
   PubMed Web of Science ®Google Scholar
• Ferraro D, Bedin R, Natali P, et al. Kappa index versus CSF oligoclonal bands in predicting multiple sclerosis and infectious/inflammatory CNS disorders. Diagnostics (Basel, Switzerland). 2020;10(10):856.
   Google Scholar
• Presslauer S, Milosavljevic D, Brücke T, et al. Elevated levels of kappa free light chains in CSF support the diagnosis of multiple sclerosis. J Neurol. 2008;255(10):1508–1514.
   PubMed Web of Science ®Google Scholar
• Ferraro D, Trovati A, Bedin R, et al. Cerebrospinal fluid free light kappa and lambda chains in oligoclonal band-negative patients with suspected multiple sclerosis. Eur J Neurol. 2019;27:461–467.
   PubMed Web of Science ®Google Scholar
• Franciotta D, Bergamaschi R, Amato MP, et al. Clinical correlations of CSF single IgG bands. J Neurol. 2005;252(10):1274–1275.
   PubMed Web of Science ®Google Scholar
• Ferraro D, Franciotta D, Bedin R, et al. A multicenter study on the diagnostic significance of a single cerebrospinal fluid IgG band. J Neurol. 2017;264(5):973–978.
   PubMed Web of Science ®Google Scholar
• Tusseau M, Cheli E, Marignier R, et al. Clinical significance of a single cerebrospinal fluid immunoglobulin band: a retrospective study. Mult Scler. 2021;27(9):1451–1454.
   PubMed Web of Science ®Google Scholar
• Melamed E, Levy M, Waters PJ, et al. Update on biomarkers in neuromyelitis optica. Neurol Neuroimmunol Neuroinflamm. 2015;2:e134.
   PubMed Web of Science ®Google Scholar
• Wingerchuk DM, Banwell B, Bennett JL, et al. International consensus diagnostic criteria for neuromyelitis optica spectrum disorders. Neurology. 2015;85(2):177–189.
   PubMed Web of Science ®Google Scholar
• Jarius S, Ruprecht K, Wildemann B, et al. Contrasting disease patterns in seropositive and seronegative neuromyelitis optica : a multicentre study of 175 patients. J Neuroinflamm. 2012;9(1):14.
   PubMedGoogle Scholar
• Graus F, Titulaer MJ, Balu R, et al. A clinical approach to diagnosis of autoimmune encephalitis. Lancet Neurol. 2016;15(4):391–404.
   PubMed Web of Science ®Google Scholar
• Mariotto S, Gajofatto A, Batzu L, et al. Relevance of antibodies to myelin oligodendrocyte glycoprotein in CSF of seronegative cases. Neurology. 2019;93(20):e1867–e1872.
   PubMed Web of Science ®Google Scholar
• Pace S, Orrell M, Woodhall M, et al. Frequency of MOG- ­ IgG in cerebrospinal fluid versus serum. J Neurol Neurosurg Psychiatry. 2021;0:jnnp-2021-326779–2.
   Google Scholar
• Akaishi T, Takahashi T, Misu T, et al. Difference in the source of anti-AQP4-IgG and anti-MOG-IgG antibodies in CSF in patients with neuromyelitis optica spectrum disorder. Neurology. 2021;97(1):e1–e12.
   PubMed Web of Science ®Google Scholar
• Carta S, Höftberger R, Bolzan A, et al. Antibodies to MOG in CSF only : pathological findings support the diagnostic value. Acta Neuropathol. 2021;141(5):801–804.
   PubMed Web of Science ®Google Scholar
• Dalmau J, Graus F. Antibody-Mediated encephalitis. N Engl J Med. 2018;378(9):840–851.
   PubMed Web of Science ®Google Scholar
• O’Riordan JI, Gomez-Anson B, Moseley IF, et al. Long term MRI follow-up of patients with post infectious encephalomyelitis : evidence for a monophasic disease. J Neurol Sci. 1999;167(2):132–136.
   PubMed Web of Science ®Google Scholar
• Menge T, Hemmer B, Nessler S, et al. Acute disseminated encephalomyelitis: an update. Arch Neurol. 2005;62(11):1673–1680.
   PubMedGoogle Scholar
• Schwarz S, Mohr A, Knauth M, et al. Acute disseminated encephalomyelitis: a follow-up study of 40 adult patients. Neurology. 2001;56(10):1313–1318.
   PubMed Web of Science ®Google Scholar
• Skotzek B, Sander T, Zimmermann J, et al. Oligoclonal bands in serum and cerebrospinal fluid of patients with HIV infection. J Neuroimmunol. 1988;20(2–3):151–152.
   PubMed Web of Science ®Google Scholar
• Goswami KK, Kaye S, Miller R, et al. Intrathecal IgG synthesis and specificity of oligoclonal IgG in patients infected with HIV-1 do not correlate with CNS disease. J Med Virol. 1991;33(2):106–113.
   PubMed Web of Science ®Google Scholar
• Kaiser R, Dorries R, Luer W, et al. Analysis of oligoclonal antibody bands against individual HIV structural proteins in the CSF of patients infected with HIV. J Neurol. 1989;236(3):157–160.
   PubMed Web of Science ®Google Scholar
• Grimaldi LE, Castagna A, Lazzarin A, et al. Oligoclonal IgG bands in cerebrospinal fluid and serum during asvmmomatic human immunodeficiency virus infection. Ann Neurol. 1988;24(2):277–1989.
   PubMed Web of Science ®Google Scholar
• Franciotta D, Zardini E, Bono G, et al. Antigen-specific oligoclonal IgG in AIDS-related cytomegalovirus and toxoplasma encephalitis. Acta Neurol Scand. 1996;94(3):215–218.
   PubMed Web of Science ®Google Scholar
• Knopman DS, Dekosky ST, Cummings JL, et al. Practice parameter: diagnosis of dementia (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 2001;56(9):1143–1153.
   PubMed Web of Science ®Google Scholar
• Waldemar G, Dubois B, Emre M, et al. Diagnosis and management of Alzheimer's disease and other disorders associated with dementia. The role of neurologists in Europe. European Federation of Neurological Societies. Eur J Neurol. 2000;7(2):133–144.
   PubMed Web of Science ®Google Scholar
• Janssen JC, Godbolt AK, Ioannidis P, et al. The prevalence of oligoclonal bands in the CSF of patients with primary neurodegenerative dementia. J Neurol. 2004;251(2):184–188.
   PubMed Web of Science ®Google Scholar
• Haussermann P, Kuhn W, Przuntek H, et al. Integrity of the blood- cerebrospinal fuid barrier in early parkinson’s disease. Neurosci Lett. 2001;300(3):182–184.
   PubMed Web of Science ®Google Scholar
• Pannewitz-Makaj K, Wurster U, Jendretzky KF, et al. Evidence of oligoclonal bands does not exclude Non-Inflammatory neurological diseases. Diagnostics. 2020;11(1):37.
   Web of Science ®Google Scholar
• Jacobi C, Arlt S, Reiber H, et al. Immunoglobulins and virus-specific antibodies in patients with Creutzfeldt-Jakob disease. Acta Neurol Scand. 2005;111(3):185–190.
   PubMed Web of Science ®Google Scholar
• Green A, Sanchez-Juan P, Ladogana A, et al. CSF analysis in patients with sporadic CJD and other transmissible spongiform encephalopathies. Eur J Neurol. 2007;14(2):121–124.
   PubMed Web of Science ®Google Scholar
• Apostolski S, Nikolic J, Bugarski-Prokopljevic C, et al. Serum and CSF immunological findings in ALS. Acta Neurol Scand. 1991;83(2):96–98.
   PubMed Web of Science ®Google Scholar
• Ticozzi N, Tiloca C, Mencacci NE, et al. Oligoclonal bands in the cerebrospinal fluid of amyotrophic lateral sclerosis patients with disease-associated mutations. J Neurol. 2013;260(1):85–92.
   PubMed Web of Science ®Google Scholar
• Goldfarb LG, Gajdusek DC. Viliuisk encephalomyelitis in the Yakut people of Siberia. Brain. 1992;115(4):961–987.
   PubMedGoogle Scholar
• Goldfarb LG, Vladimirtsev VA, Platonov FA, et al. Viliuisk encephalomyelitis in Eastern siberia – analysis of 390 cases. Folia Neuropathol. 2009;42:171–181.
   Google Scholar
• Green AJE, Sivtseva TM, Danilova AP, et al. Viliuisk encephalomyelitis: intrathecal synthesis of oligoclonal IgG. J Neurol Sci. 2003;212(1–2):69–73.
   PubMed Web of Science ®Google Scholar
• Sivtseva TM, Vladimirtsev VA, Nikitina RS, et al. Intrathecal synthesis of oligoclonal IgG in patients with viliuisk encephalomyelitis: the relationship between oligoclonal bands and clinical features. J Neurol Sci. 2018;384:84–88.
   PubMed Web of Science ®Google Scholar
• Campagnolo M, Taioli F, Cacciavillani M, et al. Sporadic hereditary neuropathies misdiagnosed as chronic inflammatory demyelinating polyradiculoneuropathy: pitfalls and red flags. J Peripher Nerv Syst. 2020;25(1):19–26.
   PubMed Web of Science ®Google Scholar
• McCombe PA, Barr AE, Brown NN, et al. Monoclonal immunoglobulin bands in the cerebrospinal fluid. Aust N Z J Med. 1991;21(2):227–229.
   PubMedGoogle Scholar
• Ben-Hur T, Abramsky O, River Y. The clinical significance of a single abnormal immunoglobulin band in cerebrospinal fluid electrophoresis. J Neurol Sci. 1996;136(1–2):159–161.
   PubMed Web of Science ®Google Scholar
• Ruiz M, Puthenparampil M, Campagnolo M, et al. Oligoclonal IgG bands in chronic inflammatory polyradiculoneuropathies. J Neurol Neurosurg Psychiatry. 2021;92(9):969–974.
   PubMed Web of Science ®Google Scholar
• Olsson T, Kostulas V, Link H. Improved detection of oligoclonal IgG in cerebrospinal fluid by isoeletric focusing in agarose, double-antibody peroxidase labeling, and avidin-biotin amplification. Clin Chem. 1984;30(7):1246–1249.
   PubMed Web of Science ®Google Scholar
• Franciotta D, Gastaldi M, Zardini E, et al. Cerebrospinal fluid total protein determination in acute and chronic inflammatory demyelinating polyneuropathies: a critical reappraisal. J Peripher Nerv Syst. 2018;23(1):70–72.
   PubMed Web of Science ®Google Scholar
• Hegen H, Auer M, Zeileis A, et al. Upper reference limits for cerebrospinal fluid total protein and albumin quotient based on a large cohort of control patients: implications for increased clinical specificity. Clin Chem Lab Med. 2016;54(2):285–292.
   PubMed Web of Science ®Google Scholar
• Breiner A, Moher D, Brooks J, et al. Adult CSF total protein upper reference limits should be age-partitioned and significantly higher than 0.45 g/L: a systematic review. J Neurol. 2019;266(3):616–624.
   PubMed Web of Science ®Google Scholar